Chris Lewis - Director, Investor Relations, Corporate Strategy & Development Thomas Burns - President & Chief Executive Officer Joseph Gilliam - Chief Financial Officer, Senior Vice President, Corporate Development Chris Calcaterra - Chief Operating Officer

Adam Maeder - Wells Fargo Securities, LLC Brian Weinstein - William Blair & Company Robert Marcus - JPMorgan Bob Hopkins - Bank of America Merrill Lynch Matthew O’Brien - Piper Jaffray Jonathan Block - Stifel, Nicolaus & Company Joanne Wuensch - BMO Capital Markets

Thank you, and hello, everyone. Joining me today are Glaukos President and CEO, Tom Burns; CFO, Joe Gilliam; and COO, Chris Calcaterra.

Following our prepared remarks, we’ll open the call to questions. To ensure ample time and opportunity to address everyone’s questions, we request that you limit yourself to one question and one follow-up.

If you still have additional questions, you may get back into the queue. Please note that all statements other than statements of historical facts made on this call that address activities, events or developments we expect, believe or anticipate will or may occur in the future are forward-looking statements.

These include statements about our plans, objectives, strategies and prospects regarding, among other things, our products, our pipeline technologies, our U.S. and international commercialization efforts, the efficacy of our current and future products, and our competitive market position, financial condition and results of operations.

These statements are based on current expectations about future events affecting us, and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Therefore, they may cause our actual results to differ materially from those expressed or implied by forward-looking statements.

Review today’s press release and our recent SEC filings for more information about these risk factors. You’ll find these documents in the Investors section of our website at www.glaukos.com.

With that, I will turn the call over to our President and CEO, Tom Burns.

Well, good afternoon, and thank you for joining us. Today, Glaukos reported another strong quarter with third quarter net sales of $43.9 million, up 9% versus the year-ago quarter and up 2% sequentially.

Given performance that has exceeded our expectations through the first three quarters of this year, we are raising our 2018 net sales guidance range to $175 million to $177 million versus our previous range of $162 million to $166 million. Joe will discuss our financial results and outlook in more detail later in this call.

In addition to delivering another record of quarterly revenues in the third quarter, we also commenced the U.S. commercial launch of the iStent inject, our next-generation Trabecular Micro-Bypass device.

As we sit here today, I could not be more pleased with the execution of our roll out strategies and the initial response of surgeons to iStent inject, leaving me more enthusiastic than ever about the product’s prospects and what it means for Glaukos going forward. We have long believed that iStent inject with its elegant and facile implant procedure would be a compelling new treatment option for U.S.

ophthalmic surgeons and patients given its stellar clinical safety and efficacy results, predictable performance, and based on our experience in international markets where over 40,000 iStent injects have already been implanted. Two months into the U.S.

iStent inject launch, these high expectations are being realized as we receive feedback from surgeons who have begun using iStent inject and reporting their initial results. Surgeons consistently highlight the straightforward nature of the implant procedure, providing them with confidence and predictability of stent placement.

They have also noticed an increased likelihood for greater IOP reductions with promising early results given to two patent bypass openings through the trabecular meshwork, which are designed to create multidirectional flow through Schlemm’s canal. This positive response was on full display at the recent American Academy of Ophthalmology Annual Meeting, where our technologies were featured in multiple surgeon presentations.

In addition to showcasing a robust iStent inject marketing campaign at the show, we held a widely-attended major MIGS educational symposia for active and potential iStent and iStent inject implanters, titled Introducing iStent inject -- MIGS Transformed, that featured an informative panel discussion with prominent key opinion leaders. Overall, we believe U.S.

surgeons’ experience to date validates what we’ve already seen in clinical literature and numerous international markets where the product has been commercially available, namely, iStent inject’s ability to achieve sustained IOP reductions that appear to be equivalent or better than U.S. pivotal trial results through a minimally-invasive, elegant tissue-spearing procedure.

From an operational perspective, the inject launch is following the same blueprint that proved successful with the original iStent, a controlled, methodical, tactical launch anchored by superlative sales rep training and skills transferred to the surgeon to achieve optimal procedural proficiency and patient safety. As we’ve always said, good outcomes translate into good long-term utilization.

We successfully completed the full training of our sales force in August and commenced full commercial launch activities in September. Our initial focus has been on converting our existing installed base of trained U.S.

iStent surgeons, and I’m happy to say, we’re tracking in line with our internal conversion expectations. Our near-term primary commercial focus will continue to be on this conversion progression well into 2019, with a gradual shift of our reps back to training new surgeons who have yet to adopt MIGS, along with increasing utilization within existing accounts.

As a reminder, iStent inject is based on the same fluidic method of action as our first-generation iStent, which over the last 10 years has been implanted in more than 400,000 eyes worldwide since its introduction and has earned an outstanding reputation of demonstrated efficacy and safety. Early surgeon feedback and initial iStent inject clinical and physician study results indicate the product and procedure comes with a superlative safety profile synonymous with our first-generation iStent.

Since our founding, we have focused first and foremost on safety. Our strategy was and is to deliver MIGS technologies that offer the most favorable benefit-to-risk calculus for the surgeon and the patient depending upon their stage of glaucoma severity.

Safety has been the foundational driver behind not only the fundamental design and size of our products, but also the clinical and commercial cadence of our initial flow of products and pipeline. The significant body of clinical and real-world experience with iStent and iStent inject represents a highly favorable device safety profile.

iStent inject represents the first in a cadence, in a cascade of anticipated new product introductions over the next five years. To that end, we continue to make great strides in advancing our pipeline of micro-scale surgical devices and sustained pharmaceutical systems for both combo cataract and standalone procedures.

We believe these pipeline platforms, if approved, will significantly expand our market opportunity at a solid cadence and uniquely transform Glaukos into the hybrid pharmaceutical device company that is well-positioned for growth and leadership well into this next decade. As we discussed on our last quarterly call, we have commenced the concurrent Phase III studies for iDose Travoprost and patient enrollment continues to proceed in line with our expectations to support our FDA approval target of late 2021 to 2022.

If ultimately FDA approved, we believe the iDose Travoprost will not only be instrumental in addressing the challenges of patient noncompliance with topical glaucoma medications, but also pave the way for a new treatment algorithm where surgeons use iDose alone or in combination with other therapies, including our portfolio of surgical flow devices to more effectively manage patients’ IOP. Further, we believe the powerful iDose Travoprost data available thus far underscores the potential of our iDose drug delivery platform to produce future generations of sustained therapies for glaucoma and potentially other ocular diseases.

While we actively recruit our iDose pivotal trials and await the associated recommencement of our iStent SA pivotal trial, we’re happy to announce we have commenced patient enrollment for our 510(k) pivotal trial for the iStent Infinite, our three-stent standalone product for advanced and refractory glaucoma patients well ahead of our initial timing expectation by year-end. As a reminder, this would be a prospective, multi-center, single-arm clinical trial that will enroll roughly 65 refractory subjects.

We continue to target FDA approval for iStent Infinite in the late 2020 to 2021 time period. Finally, the two-year patient follow-up in the pivotal trial for iStent Supra, our suprachoroidal stent will be completed in the first quarter of 2019 and we continue to target FDA approval in 2020.

As we’ve said all along, we continue to see the suprachoroidal space as a potential second-line MIGS treatment option for more moderate to progressive open-angle glaucoma patients given its higher risk-to-benefit profile versus the trabecular meshwork. We look forward to closely working with the FDA for this product once the pivotal data becomes fully available next year.

As a result of the notable progress we are making on all fronts of our business and as we turn the corner towards 2019, we are accelerating key investments we’re making for the future. These investments span across all major facets of our business, including in R&D.

With the success we’ve seen in the advancement of our flow and pharmaceutical platforms, we continue to add highly-talented scientists, chemists and engineers to form a powerful team equipped with state-of-the-art equipment to pursue early-stage product development, novel sustained pharmaceutical systems and platform optimization. In clinical and regulatory, we’re optimizing our worldwide leadership and organizational structure and adding resources internally that expand our capabilities and presence in the field to support global clinical study requirements, targeted regulatory approvals and post-approval studies.

We are moving forward investment to enhance and upgrade our global systems capabilities and to broaden our technology infrastructure to support this future growth. And finally, in our commercial organization, we continue to invest and expand our sales force, marketing and market access teams, both in the U.S.

and abroad. As you know, the expansion of our direct sales presence in key international markets has been an important recent investment focus for us.

In addition to the 16 international countries, where we have a direct market presence today and continue to add resources, we are evaluating making initial investments in potential new international markets where we hope to enter in the coming years. The investments to date are being validated as the momentum continued to build internationally during the third quarter with OUS sales growth of 57% year-over-year.

Our growth continued to be broad-based globally with Australia, Germany, Japan and UK leading the way. In Australia, the permanent reimbursement code covering the implantation of iStent and iStent inject in combination with cataract surgery became effective on November 1.

While we’ve been impressed with our team’s ability to sustain growth in this region despite not having any professional fee reimbursement, we are pleased to have secured appropriate economics for implanting physicians in Australia. Combined we believe the investments we are making today will help to fuel our continued growth and solidify the foundation from which our franchise can significantly expand over time, as we advance our aspirational mission to transform Glaucoma therapy.

So with that, I’ll turn the call over to Joe for summary of the third quarter financial results. Joe?

Thank you, Tom. As noted earlier, net sales for the third quarter of 2018 were $43.9 million, a year-over-year increase of 9%.

The U.S. represented 83% of our sales in the quarter, and international 17%.

In the U.S., third quarter 2018 sales were $36.4 million, up 2% from the same period a year ago. U.S.

sales in the quarter were impacted by channel destocking ahead of customer conversions from iStent to iStent inject as expected, which was partially offset by the competitive market developments late in the quarter. ASPs remain stable year-over-year and versus prior quarters.

Outside the U.S., third quarter sales were $7.5 million, an increase of 57% from the same period a year ago. Our international business continued to outperform expectations, as core market growth more than offset EU summer seasonality headwinds.

This quarter, Australia, Germany, Japan and the UK drove the majority of the year-over-year increase led by growing iStent inject sales. Our gross margin in the third quarter was roughly 86.3% versus 85.9% in the same quarter in 2017.

We continue to expect our gross margins to remain in the mid-80%s range going forward, as we navigate the U.S. inject launch from an operations perspective.

SG&A expenses in the third quarter rose 31%, to $31.6 million versus $24.1 million in the year-ago quarter. This rise reflects higher personnel and other costs related to the ongoing expansion of our domestic and global infrastructure, primarily in our commercial and international operations and investments associated with the iStent inject launch.

R&D expenses rose 35% in the third quarter to $13.2 million versus $9.8 million in the same year-ago period. This rise reflects primarily the costs of additional personnel as we expand our pharmaceutical R&D capabilities and within clinical affairs, where in particular the direct costs associated with the iDose trial enrollment continues to increase.

We finished the third quarter with a net loss of $6.6 million, or $0.19 per diluted share, compared to net income of $1.3 million, or $0.04 per diluted share in the third quarter of 2017. As of September 30, 2018, we had cash, cash equivalents and short-term investments of $137.8 million, compared to $120.1 million at the end of the second quarter 2018.

As we’ve said before and consistent with Tom’s remarks regarding investments we are making, it’s important to remind you that as we progress through 2018 and into 2019, our primary focus remains on long-term growth as we prudently invest to build the MIGS market, drive increased penetration of our iStent and inject platforms globally, drive our robust pipeline initiatives through necessary clinical studies and programs and advance new opportunities in the clinical studies. Finally, as Tom indicated earlier, we are raising our 2018 net sales guidance to $175 million to $177 million, up from our previous range of $162 million to $166 million.

This guidance outlook takes into account our continued organic outperformance, the updated MIGS market landscape, the new doctor training and destocking dynamics associated with our Inject launch and the expansion of our international sales, which we now expect to be at least $28 million for the full year, up from our previous range of $25 million to $27 million. With that, I’ll now turn the call back to Tom.

All right, thanks, Joe. So to recap, Glaukos delivered strong financial performance in the third quarter with record revenues while achieving a major commercial milestone with the commencement of the U.S.

commercial launch of iStent inject. I’m very pleased with the initial roll out of iStent inject and with the early surgeon feedback that reinforces our confidence in the product’s potential to drive MIGS closer to becoming a standard of glaucoma care.

As I think about the future of our business, I remain convinced that the substantial investments we’re making today to deliver our pipeline and to expand our franchise can fuel sustained growth for many years to come. I want to thank the more than 400 Glaukos employees who dedicate their talents, determination and energy to advancing our aspirational mission to transform glaucoma therapy.

I’m very optimistic about the franchise we’re building and I believe in the proven ability of our team to continue to create meaningful shareholder value. So with that, I’ll open the call to questions.

Operator?

Hi, guys. It’s Adam Maeder on for Larry.

Thanks for taking the questions. I wanted to start with a question on next year.

So as we start looking ahead to 2019, there are a handful of moving parts. I think, the expectation is for about 20% U.S.

market growth in 2018. Should we be thinking about a similar rate of growth next year with a full-year of inject and no CyPass in the market?

Would you expect to largely capture all of the available CyPass share next year, and just any thoughts on trialing in 2019 from Ivantis? And then I had a follow-up.

Hey, Adam, it’s Joe. I might take that a little in reverse.

So I think, we’ve been on record with respect to CyPass share recapture that it’s really – it’s not going to be a one-to-one correlation. I think that’s – the marketplace is still evolving as we move forward here, but I think we remain of that view that we expressed in the early days post the recall.

As we turn the corner to 2019, we’re obviously not going to give guidance here today, but I think I can provide a little incremental color that will hopefully be helpful as folks think about the trends heading into 2019. We do feel good about the underlying market growth dynamics heading into the year, as Tom indicated in his remarks.

From a doctor conversion to inject standpoint, we would expect to end the year with approximately half or at least half of our doctors in the training funnel, and that’s ahead of our original expectations as we enter the launch period. What does that translate into the dynamics that we’ve discussed on prior calls?

It means that one, the conversion of doctors to iStent inject will continue well into 2019. Two, it means that the sales force will gradually return their focus to new doctor and same-store sales expansion over the course of 2019.

Three, it means the channel destocking should largely subside from a macro standpoint as we enter the year. And lastly, finally, we would expect that the lack of new doctor training in the second-half of 2018 would have a lag effect in the first-half of 2019.

So hopefully that gives you some color around how we’re thinking about the setup going into the year, both from a market perspective as well as a Glaukos specific perspective.

That’s helpful. Thanks.

And then just for my follow-up, I was hoping you guys could level set us on the current status of reimbursement. It looks like the calendar year 2019 facility fee is favorable once again.

On the physician side, Novitas recently lowered the physician reimbursement for 0191T, I think, to around $370 or so. How many of the MACs are now in this $300, $400 range?

And then you’re also seeking incremental reimbursement for inject with 0376T. How many of the MACs are providing additional reimbursement for this code?

And just any comments around the impact that you’ve seen the same-store sales growth following these cuts to physician reimbursement in the past? Thanks for taking the questions.

Okay. Hey, Adam, this is Chris.

Let’s start out with the regs that came out for next year. We were quite pleased with those.

For the ASC setting, it’s about $114 incremental payment over 2018. And in the hospital HOPD, it’s about another $30, I believe.

So these are incremental and that’s a very positive thing. As it relates to Novitas, they did reduce their professional fee down into that $370 range, which is in line with what we’ve been communicating to everyone that we felt that it needed to be between that $300 to $500 range.

There’s only one MAC that has not reduced their fee and that’s First Coast in Florida. They’re at the $800 range.

And as we’ve guided you guys in the past, we would expect at some point for them to do the same. We still feel that within that band, that $300 to $500 range, there’s plenty of incremental dollars for a physician to be adequately reimbursed for implanting iStent or iStent inject.

As it relates to 0376T, this is an add-on code. This is a code that some – that we’re encouraging people to utilize when they implant iStent inject.

This would be above and beyond what they would get for implanting an iStent, in this case a second iStent Inject. We have one MAC that is covering it and others that have been sporadic in their coverage of it.

We’re hopeful that this will be something that all the MACs will adopt. But we still think if that doesn’t happen that there’s enough here to have a favorable prophy [ph] response for implantation of iStent inject.

Great. Thank you very much.

Hey, guys, thanks for taking the question. Can we talk about market growth expectations here?

I think it was alluded to just before and you guys have consistently commented on 20%. Is that still what you’re seeing?

Did you see any slowdown or have you seen any slowdown? Do you anticipate seeing a slowdown as a result of the safety concerns with CyPass into the market?

We’ll start with that and then I’ll have a follow-up. Thanks.

Hey, Brian, is Joe. So first and foremost, the 20% target that we expressed on the guidance call for 2018 was a full-year target.

And I think we were pretty consistent on the subsequent calls of saying what we really expect was that to be somewhat front-end loaded and to be disrupted by our own activities in the second-half of the year, specifically around the iStent inject conversion. And I think that’s exactly how it’s played out over the course of the year.

In the first-half, we saw market growth that exceeded 20% from an organic perspective. And as we got into the third quarter, we – I think, we saw growth that was a little bit below 20%, and again, not surprisingly given that new doctor growth slowed substantially and we saw channel destocking ahead of the inject conversion.

Okay. And then, Tom, it sounded like when we met in Chicago last weekend or whatever it was two weekends ago, that you guys were excited obviously about inject.

But that one of the things that it seemed like it came – that came out was the notion that clinicians may be seeing better IOP reduction than what was seen in the clinical trial. Can you just talk to why that may be the case?

I recall that as we saw iStent play out, we saw better results in the real world over time. But can you just talk about what, specifically, you’ve been hearing on that and the importance of that?

Thanks.

Yes, I’d be happy to. So I think, what we’re seeing with iStent inject mirrors what we saw with iStent.

In the pivotal trial on iStent and subsequent to that, we saw progressively more marked reductions in intraocular pressure as surgeons became more facile with the procedure, understanding placement within the trabecular meshwork, understanding how close or far apart to place the stents, two areas where they felt they were getting full flow into the episcleral venous system. Likewise, I think, we’re seeing the same thing here.

We’re seeing surgeons that even though this is a very facile, elegant procedure, there are nuances that can be adapted as they incorporate new sclerals, which allow them to get even greater pressure reduction. So as I think all of you are doing your channel checks, I think, you’re hearing the same things we’re hearing, which are surprisingly strong and robust reductions in intraocular pressure that appear to be better than what we saw in the U.S.

pivotal trial. So I think, it’s all seasoning and I think incorporation in facility and use of the procedure over time.

Great, and congrats on the good quarter. I was hoping you guys can help us understand the current dynamics in the market.

So now with CyPass off, help us understand how doctors are thinking about MIGS. Before I had always had the understanding that it was a toolbox approach – we use some for certain patients, some for other patients.

But I always had the understanding that doctors wanted to use MIGS, because there aren’t a whole lot of other options for these patients. So, I understand not every patient is going to go from – that you lost in CyPass or that they lost in CyPass sales to iStent.

But help us understand what you’re hearing from physicians around the decision making of patients that maybe would have formerly had CyPass? And where – how they’re getting treated today?

I’ll ask Chris to respond, and I may add some color.

Hey, Robbie. So as time went on, the CyPass device – and not in all cases, but tended to move to more moderate to advanced glaucoma.

And that was, as we’ve always said, had a lot to do with the risk-to-benefit calculus associated with that product. So those devices that are now off the market, I think, some doctors are looking at iStent inject, but they’re also looking at the all other bucket.

And the all other bucket, as we describe it, is primarily utilized by glaucoma specialists who are treating most of these moderate to advanced glaucoma patients. That’s the Omni, the different canalicular devices, et cetera.

So that’s where most of the glaucoma specialists are going. With the cataract comprehensive guys, they’re certainly looking at us.

We would expect that they would look at the other competition as well. So that’s where it is right now.

And I think it was obviously beneficial for us in terms of the timing of our introduction of iStent inject.

Yes, I would just add that. As we’ve said all along, we felt and we said that with the CyPass as well that we thought that glaucoma specialists would be more attracted to the use of a suprachoroidal stent, because they have a higher degree of tolerance for some of the collateral and sequalae that can be associated with the product, and because a lot of times they’re digging deep and trying to get as profound pressure reductions as possible.

So even though the means of suprachoroidal stent and trabecular bypass stents tend to be similar in clinical trials. Because of the episcleral venous backpressure associated with trabecular bypass stents, we’re not going to see pressures in – typically in the 6 millimeter to 8 millimeter range.

And this is where glaucoma specialists are trying to reach for certain candidates. So they don’t have to move to a trabeculectomy or to an aqueous shunt procedure.

So this is the niche area that we think that suprachoroidal stents largely define. We’ve said this now since we’ve gone public.

And because of that, because of that niche, we think they’re – this is why there’s not going to be a – typically, a one-to-one conversion. Because as you know, as powerful as our trabecular bypass stents are, they’re not going to invariably reach down to the 6 millimeter to 8 millimeter target range that you need with some of these very, very progressive patients.

Now, what that portends though is the need for when we have a suprachoroidal stent, we may have the opportunity to fill that niche. And so we remain optimistic about the algorithm.

We’ve been very consistent about the placement, and by the way, this has played out, I think, very, very similar to what we’ve said in the marketplace since our IPO. And we expect that we’ll have the full treatment algorithm in the future to treat all disease state severities.

And Robbie, from a market modeling perspective, when we’ve quoted and talked about 20% growth, we’ve never included those late-stage procedures such as tubes, or trabs, or even a XEN-type procedure in those estimates.

Okay, great. That’s helpful.

And maybe a follow-up, Joe or Chris. The spending in the quarter was a bit higher than I had expected.

Maybe help us understand as you’re launching inject, as you’re converting the market, help us understand what sort of selling and marketing activities are going on? And maybe if you could give us any thoughts on the trend line into 2019, that would be really helpful?

Thanks.

Hey, Robbie, I’ll start out at a high level on the sales and marketing. With a product like this, we made significant investments into the promotion of this product.

We had some robust marketing activities at the AAO. We’ve had some activities associated with advertising and then certainly the training of the sales organization, all of which were moved up, if you will, because of the early approval of iStent inject.

Yes, and it’s Joe. I would just add.

In addition, there’s obviously all the promotional activities in terms of the training activities and the products used in training and things like that, that are incremental costs associated with the launch. And then on the R&D side, largely as expected, right?

I mean, as we continue to pick up steam in the iDose trial in particular, you’re going to see that R&D and clinical spend continue to accelerate going forward and into the 2019 time frame. So some expenditures in the quarter that were a little bit more one-time in nature.

But generally as you heard Tom say, we’re continuing to prudently invest and reinvest in the business for the long-term future, both commercially as well as from an R&D perspective.

Thanks a lot.

Thanks and good afternoon. Joe, if okay, I wanted to start with you.

You made a few comments around things to consider for 2019, and I appreciate those comments. But there’s a lot of moving parts to 2019, and I’m not 100% sure of the net, kind of take-home around your comments beyond it’s not going to be a perfectly clean year.

So my initial take when I put all these comments that you’ve made together, is that the consensus of $231 million probably is a little too aggressive given some of the things that you said, but I’m not really sure of that. And I just wanted to ask preliminarily, am I reading your comments correctly?

Well, I appreciate the question, Bob. I mean, I think, obviously, we’re not going to give guidance sitting here on this call or endorse specifically where the Street is at, beyond trying to give some incremental color.

I think it’s a unique situation heading into this call obviously with what transpired during the quarter and folks had to put together a pretty significant change in their models, both for the remainder of this year and going into next. Hopefully, the guidance that we’re giving for 2018 is an important data point to level-setting expectations around where the business is headed.

And then we try to give some incremental color around those growth drivers heading into next year. Make no mistake, I think what you’re hearing from Tom, Chris, myself is optimism with respect to the market development and what’s happening fundamentally underneath it and inject being an important driver of that for us.

We’re ahead of schedule on that. We feel very good about what that means as we head into 2019.

My comments were designed to help you get a bit more granular, as you think about what that translates into quarter-in and quarter-out over the course of 2019, and once you’ve already level-set based upon the guidance we’ve given in 2018.

Yes, I appreciate that and I hear the optimism and I think there’s reason – clear reason to be optimistic. And there’s just some things that will impact, like channel stocking.

Like, we can’t model channel stocking, doctor conversions, these are some things that are just very challenging as outsiders to model. So I was just trying to get some sort of quantification of those kind of temporary headwinds, if you will, or just trying to make sure I understood what the message is, given the uniqueness of the situation we’re in right now.

No, I certainly understand that. I think if you think about it even from the perspective of communicating at another level of granularity.

It’s – within these accounts, you have multiple doctors within an account. If one was a CyPass user, two were being trained on inject, there’s some destocking activity, there’s enough moving parts there that it becomes pretty difficult to quantify in a way to break down each individual component for you to model that.

But what I can say, I guess to sort of put a finer point on a couple of them, we are saying going into 2019, just to be clear, that we think the channel destocking should be largely behind us, right…

Okay.

...that if you think about it from a doctor conversion standpoint, what I said was that we expected to enter 2019 with more or at least half of our doctors in the training funnel. If you get past that halfway mark, then you sort of offset each other between restocking of customers who are now on inject versus destocking of the ones that are still being trained and it becomes a net neutral, right, as you enter into 2019.

I think you can also take from that data point around where we’ll be at from a training standpoint, as the pace in which we’re converting existing iStent users to inject. And that should help you as you think about the cadence of what that means for the business into 2019.

And then really, the last thing I tried to highlight was, I don’t want to get lost, which is, as we’ve had a pretty substantial and as we forecasted a pretty substantial slowing of new doctor training, that’s not just a second-half of 2018. There will be some lag effect associated with that as we start the market or the year off in 2019 from a market growth perspective.

Okay, that’s super helpful. I appreciate it.

And then lastly, just quickly, I completely hear what you guys are saying in terms of Alcon not being one-for-one, that makes total sense. But I’m still curious, do you guys – what is your best estimate as to what the Alcon run rate was with CyPass at the time of the recall?

Well, Bob, it’s Joe. I think, we have a pretty good sense of what that run rate was.

We’re somewhat prohibited from getting too granular given confidentiality obligations and the like. But I will say, maybe the one comment I’ll say is, I think, when I look back at some of the modeling that was done across the buy-side models for 2017 and even 2018, I think folks were a little bit ahead of the true run rate of CyPass during that timeframe.

But beyond that, I can’t get much more granular.

Okay, great. Thanks very much.

That’s all I’ve got.

Thanks, Bob.

Good afternoon, and thanks for taking the questions. Just as a starter, and I know it’s early days here.

But can you just give us any kind of sense for the utilization in your inject accounts here in the U.S.? Is it higher than what you were citing with iStent alone?

It’s Joe. I think you’ve sort of set it up the right way, Matt.

It’s a little bit early for us to probably be commenting on that. I think, we’ve all been on record that the product itself and in the surgeon’s hands, they like using it, right?

And so, I think that sets up well for expanded utilization as we make our way into 2019. But I think it’s just too early to be seeing those trends develop now.

Anything you can provide qualitatively as far as introductions in Europe or OUS countries?

Yes, as we said in the past, Matt, we’ve been very pleased with what’s happened in Australia and Canada and Germany, and now the UK with iStent inject. And I would say that we’ve had similar feelings here about the U.S.

The reception for iStent inject has been very positive. I couldn’t be more pleased with the execution and the roll out strategies of this campaign.

Doctors are enthusiastic about the product. They are pleased with their outcomes.

They’re – as we’ve spoken before, they’re pleased with the predictability of it, the elegance of the procedure, the ease of use and certainly the outcome. So things are going very well.

Our challenge, Matt, on trying to extrapolate from the OUS experience is just the in is so small outside the U.S. If you were doing $1 million of sales in a country and you launch Inject and you do $2 million, I don’t think that’s in a trend that you can extrapolate directly United States given we’re just at a different stage of market development.

Yes, that’s fair. And then as my follow-up.

As I look at the Q4 guide here, it’s up, easy math, about $6 million sequentially. This time last year you were up about $1 million.

So is that a – I know there’s some destocking in there, so that’s a little bit of a headwind. But that bump there – and again, international is doing well, but that bump feels like it’s largely attributable to the CyPass coming off the market.

Is that a fair way of viewing kind of the impact there? And again, not getting the full impact of CyPass being off the market in Q4, but some level of contribution?

If you want to – I don’t – I’m sure you’re not going to quantify for us here. But just some way of kind of looking at that bump that we’re seeing here as maybe 50%, 60% of the CyPass utilization in the U.S.

and we can kind of use that as a baseline to start thinking a little bit more about 2019?

Yes. Well, I think, Matt, first, the guidance increases is about $12 million from midpoint to midpoint and international accounts for about $2 million of that, U.S.

accounts for about $10 million. I think all I can say with respect to the – I think the heart of your question is, it really is a combination of continued, what I’ll call, organic outperformance, i.e., without the benefit of the recall activities and then an evaluation of all the Q4 scenarios.

And there’s a lot, as alluded to in this call, a lot of puts and takes that we’re evaluating with respect to the remainder of the year. So it’s both that outperformance that we’ve seen and we continue to see, as well as incorporating scenarios around a lot of factors, including the pickup from the CyPass recall.

Fair enough. Thank you.

Great. Thanks.

I want to ask probably too straightforward of a question. But just curious, has been off the market for roughly two months and change, and you guys are obviously interfacing with many more docs than we are in our end.

So Tom or Chris, just a blanket statement. If there were 100 CyPasses being done in the market by a doc, can you give us – we all understand it’s not a one-for-one, but is it a 0.5-to-1, a 0.2, a 0.7?

Maybe if you can just give a little bit more detail on how you think and where those procedures are going? And then I’ve got one or two follow-ups.

Well, It’s Joe. I mean, Tom or Chris can comment qualitatively on what we’re seeing and hearing from the marketplace.

But quantitatively, I don’t think we can get more granular than it’s not one-to-one. I think you have conversations in the community, there’s a wide variety of that depending upon the type of doctor that you’re talking to.

A Glaucoma specialist who is seeing a lot of late-stage patients that might have been using CyPass, to Chris’ earlier commentary, might be shifting a decent chunk of those to tubes and trabs, or XEN and procedures like that. For the comprehensive doctor who is seeing more of that moderate patient they might have been using CyPass on, I think, we’re picking up a pretty good chunk of that.

How all that translates over time, we haven’t – we’re just not going to get more granular than it’s not one-to-one.

Okay. Let me try maybe a different approach.

Joe, I guess, I’ll stick with you, then. I believe mid to high-teens year-over-year growth seems implied in your U.S.

number for the fourth quarter of 2018 and that’s with CyPass off the market for the entire quarter. So should we think about that’s sort of the baseline and that’s slightly suppressed by the channel that you mentioned?

And that unwinds in 2019? And please let me know if that makes some sense.

In other words, again, you’ve got the high-teens implied in the U.S., but that high teens is being suppressed by the elements of the channel, which should unwind next year? And then I’ve got one last one for you.

I think that’s a good question, Jon. I think that’s – as you think about unpacking it, as it turns towards 2019, obviously within a margin of error, because there are a fair number of puts and takes in that and things that will be evolving going to next year.

But that’s not a bad way of thinking about the trend heading into 2019.

Okay, that’s my goal, not a bad way. Last one for you, Chris.

Chris, just thoughts on new docs being trained, moving parts? I’m guessing inject has them excited.

You’ve got better pressure drops and easier procedure to perform. Are you hearing any concerns or any offset to that regards to ECL and safety when you reach out and you hear back from the next wave of potential adopters?

Thanks for your time, guys.

First, just to remind you, Jon, that we’re focused completely right now on converting our existing customers over to iStent inject. So people that have been using iStent, whether they used it exclusively or in combination with other products, these are the guys we’re focusing on.

So those that are on the sideline with MIGS will be coming along after we get through that training of our existing docs, which as Joe mentioned, will be sometime during the course of 2019. But yes, there is people very interested in iStent inject.

I do think it’s a product that will help to expand the marketplace and we will get to those people in due time.

Good afternoon, and thank you very much for taking the questions. I have some product pipeline questions.

Your commentary on the suprachoroidal stent, it’s interesting because one of the – in our doctor due diligence, one of the things that seemed to be the "CyPass Problem" was where in the eye it was placed. How do you – if that is the right information or your view too, how do you compare that to continuing down the road with the suprachoroidal stent of your own and not just sort of redirect those funds and those efforts elsewhere?

Yes, good question, Joanne. This is Tom.

I’m happy to take this one. So what I would tell you is that, as we’ve said for sometime now, since this issue came up and the voluntary withdrawal from Alcon took place, the anatomy in that angle certainly is one of the conditions that we think leads to the endothelial cell loss.

But by Alcon’s own admission, they found a tight correlation between the number of retention arches that were visible, that were actually in a way proud of the ciliary muscle attachment, they have a high correlation with endothelial cell loss. And it makes sense, because the more retention arches that show, that means that the suprachoroidal stent is higher in the anterior chamber and then it predisposed to touch the endothelial cells of the cornea.

And they’ve made – they have actually a proportional analysis showing the number of retention arches that show and the correlation with endothelial cell loss. And this can be either due to improper placement or potentially just some migration over time.

So these are really powerful issues that, that really have led to the endothelial cell loss. When you look at what we have with our suprachoroidal stent, we will determine and look at the data when it’s available, last patient should be at the end of the first quarter next year, but there are some really seminal differences between our product and theirs.

Our product is far shorter. The product is only 4 millimeters in length versus 6.3, so less than 50% of the length, but actually less than 50% of the inner diameter and outer diameter.

So it’s a far more micro-invasive device. Secondly, our device has a radius of curvature which follows the natural scleral entry path into that potential space, which may have some ability to then curve it away from the endothelium and the kind of perpendicular nature of more of a straight shunt that you’ve seen with the Alcon device.

Again, the data will be telling. So we think there are other differences as well.

We don’t have fenestration holes in our suprachoroidal stent, which we think are – offer an ability for cells to migrate and basically become an obstructive mechanism within the stent and our stents are coated with Heparin. All of these, which we think give us the ability to perhaps provide for sustained therapy and maybe give us some appositional types of changes, which may alleviate some of the risk of endothelial cell loss.

So it’s a long-winded answer, but I think it answers your question. The data will be telling, we’re optimistic.

We know that there’s an appetite for this kind of a product you know it as well with the glaucoma community rather than having to go to a shunt, an aqueous shunt or to a trabeculectomy. So we think that we want to continue on course and try to fill this niche in the future.

Thank you. As my second question I want to go back to your commentary regarding inject and the roll out of it.

My impression from talking with physicians is one of the things that they like inject is that it’s easier to use, and at some stage we have theorized that the doctor sitting on the sidelines with an easier to use product will now get into sort of the MIGS program. How do you think about going to them in the wake of CyPass with reimbursement, somewhat better in certain situations, somewhat not so much, and asking them to say, okay, I know Dr.

Jones, you haven’t been using a MIGS device, now start to use inject. And how do you approach that physician throughout 2019 and ramp on the new doctor?

Thank you.

So, Joanne this is Chris. And really, we focus on the safety message here.

Trabecular bypass is definitely safer, has less sequelae associated with it than a suprachoroidal shunt. And we sell the benefits and features of that, the safety profile, and then, of course, the efficacy that you get from having two patent bypasses.

So that message is resonating. I think it’s being well-accepted.

I think, to your point, the ease of use, also plays into that. And with those three things in mind, I do think that this is a product that people who have been sitting on the sidelines or who are unhappy with the voluntary recall of the CyPass device will be energized when they get this in their hands.

And Joanne, I wanted to use this as an opportunity to, I think, completely retire an issue. And the issue is one of whether the endothelial cell loss associated with suprachoroidal has any class correlation, or does it affect other MIGS devices.

And I’m really terribly delighted, as many of you know, to talk about the FDA’s recent pronouncement that there is no evidence to date that this is a class issue, that there is any endothelial cell loss associated with other MIGS devices, primarily our trabecular bypass devices. I use this again as an opportunity to say, in the trabecular bypass space, we’ve been commercialized over 10 years.

We have over 400,000 implants commercially that have been sold of many, many others in clinical trials. We studied for over 6.5 years adverse events in the U.S.

pivotal trial and the first with the classic stent, and we found no statistical difference in SAEs between iStent and iStent plus cataract versus cataract surgery alone. So again, I wanted to reassure and hopefully retire the issue completely that there is any correlation of endothelial cell loss with the trabecular bypass space, and particularly with our iStent products.

Thank you.

Okay. Well, listen, I want to thank all of you for your time and attention today and to our investors for your continued support and interest in Glaukos.

Thank you, and goodbye.